Case reports in nephrology and dialysis · 2025
Immune Checkpoint Inhibitor - Associated Renal Tubular Acidosis and Nephrogenic Diabetes Insipidus: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cohen Ido, Qormata Loaa, Erman Orit, Vardi Iddo, Mayan Haim, Mouallem Meir
Аннотация
INTRODUCTION: Immunotherapy has significantly changed the landscape of cancer treatment, yet it can lead to immune-related adverse events, including renal complications. This report highlights a unique case of tubular injury associated with pembrolizumab in a patient with malignant melanoma.
CASE PRESENTATION: A 42-year-old female patient with malignant melanoma received adjuvant pembrolizumab treatment. Three months later, she presented with profound weakness, myalgia, abdominal pain, polyuria, and thirst. Laboratory tests revealed acute kidney injury, significant proteinuria, renal tubular acidosis (RTA) with severe electrolyte imbalances, and nephrogenic diabetes insipidus (NDI). Management involved withholding pembrolizumab, initiating high-dose prednisone therapy, and correcting hypokalemia and metabolic acidosis. The patient showed rapid clinical improvement, with normalization of renal function and symptom resolution, allowing for discharge within a week. A follow-up visit confirmed no residual renal impairment.
CONCLUSION: This case emphasizes the importance of recognizing renal complications in patients undergoing treatment with immune checkpoint inhibitors. Awareness of potential adverse effects such as RTA and NDI is crucial for prompt identification and management to prevent lasting damage.
CASE PRESENTATION: A 42-year-old female patient with malignant melanoma received adjuvant pembrolizumab treatment. Three months later, she presented with profound weakness, myalgia, abdominal pain, polyuria, and thirst. Laboratory tests revealed acute kidney injury, significant proteinuria, renal tubular acidosis (RTA) with severe electrolyte imbalances, and nephrogenic diabetes insipidus (NDI). Management involved withholding pembrolizumab, initiating high-dose prednisone therapy, and correcting hypokalemia and metabolic acidosis. The patient showed rapid clinical improvement, with normalization of renal function and symptom resolution, allowing for discharge within a week. A follow-up visit confirmed no residual renal impairment.
CONCLUSION: This case emphasizes the importance of recognizing renal complications in patients undergoing treatment with immune checkpoint inhibitors. Awareness of potential adverse effects such as RTA and NDI is crucial for prompt identification and management to prevent lasting damage.